We could not find any results for:
Make sure your spelling is correct or try broadening your search.
SOUTH SAN FRANCISCO, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Septerna, a clinical-stage biotechnology company pioneering a new era of GPCR-targeted drug discovery, today announced that Jeffrey...
Deep Pipeline of GPCR Programs Focused Initially on Indications in Endocrinology, Immunology and Inflammation, and Metabolic Diseases Phase 1 Clinical Trial Ongoing for SEP-786, Oral Small...
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR...
SOUTH SAN FRANCISCO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.86 | -7.27984344423 | 25.55 | 26.69 | 20.61 | 139081 | 22.88553251 | CS |
4 | -1.21 | -4.859437751 | 24.9 | 28.99 | 20.609 | 507810 | 23.88808467 | CS |
12 | 0.19 | 0.808510638298 | 23.5 | 28.99 | 18.62 | 343909 | 23.47240701 | CS |
26 | 0.19 | 0.808510638298 | 23.5 | 28.99 | 18.62 | 343909 | 23.47240701 | CS |
52 | 0.19 | 0.808510638298 | 23.5 | 28.99 | 18.62 | 343909 | 23.47240701 | CS |
156 | 0.19 | 0.808510638298 | 23.5 | 28.99 | 18.62 | 343909 | 23.47240701 | CS |
260 | 0.19 | 0.808510638298 | 23.5 | 28.99 | 18.62 | 343909 | 23.47240701 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions